REG - Adage Capital Prtnrs Amgen Inc. Horizon Therapeutics - Form 8.3 - Horizon Therapeutics PLC

AmgenAnnouncement

31/08/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe9895Ka&default-theme=true

RNS Number : 9895K  Adage Capital Partners LP  31 August 2023

Ap19

 

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER
RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR
MORE

 

1.       KEY INFORMATION

 

 Name of person dealing (Note 1)                                                Adage Capital Partners GP, L.L.C.

 Company dealt in                                                               Horizon Therapeutics PLC
 Class of relevant security to which the dealings being disclosed relate (Note  US$0.0001 ordinary shares
 2)
 Date of dealing                                                                30(th) of August 2023

 

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the
class of relevant security dealt in (Note 3)

                                              Long                                Short
                                              Number                  (%)         Number      (%)
 (1) Relevant securities                      3,394,606        1.48%
 (2) Derivatives (other than options)
 (3) Options and agreements to purchase/sell
 Total

 

(b)        Interests and short positions in relevant securities of the
company, other than the class dealt in (Note 3)

 Class of relevant security:                   Long             Short
                                               Number      (%)  Number      (%)
 (1) Relevant securities

 (2) Derivatives (other than options)

 (3) Options and agreements to purchase/sell
 Total

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 Purchase/sale   Number of relevant securities   Price per unit (Note 5)
 Sale            50,000                          113.50

 

 

(b)      Derivatives transactions (other than options transactions)

 

 Product name,      Nature of transaction  Number of relevant securities  Price per unit

 e.g. CFD           (Note 6)               (Note 7)                       (Note 5)

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

 Product name,      Writing, selling, purchasing, varying etc.  Number of securities to which the option relates (Note 7)  Exercise price  Type, e.g. American, European etc.  Expiry date  Option money paid/received per unit (Note 5)

 e.g. call option

 

 

(ii)      Exercising

 

 Product name,      Number of securities  Exercise price per unit (Note 5)

 e.g. call option

 

 

(d)      Other dealings (including transactions in respect of new
securities) (Note 4)

 

 Nature of transaction  Details  Price per unit

 (Note 8)                        (if applicable) (Note 5)

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 Full details of any agreement, arrangement or understanding between the person
 disclosing and any other person relating to the voting rights of any relevant
 securities under any option referred to on this form or relating to the voting
 rights or future acquisition or disposal of any relevant securities to which
 any derivative referred to on this form is referenced. If none, this should be
 stated.

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note
9)
 NO

 

 Date of disclosure                                                30(th) of August 2023
 Contact name                                                      Chris Palmer
 Telephone number                                                  617-867-2514
 If a connected EFM, name of offeree/offeror with which connected
 If a connected EFM, state nature of connection (Note 10)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ITPBBGDIUDXDGXB